NOTE 22: - BALANCES AND TRANSACTIONS WITH EXECUTIVE OFFICERS AND CERTAIN SHAREHOLDERS

As reported by the shareholders, and based on publicly available information, as of December 31, 2024, Corteva (through its subsidiary Pioneer Hi-Bred International, Inc.) holds 27.26% of the Company's subsidiary shares )Lavie Bio Ltd.’s(. In addition, Corteva is a major customer (see Note 21c, customer A).

Balances:

Balance at December 31, 2024:

	Executive officers		Certain shareholders

Receivables	$	-	$	167
Other payables	$	322	$	-

Balance at December 31, 2023:

	Executive officers		Certain shareholders

Receivables	$	-	$	186
Other payables	$	557	$	-

Benefits to directors:

	Year ended December 31,
	2024		2023		2022

Compensation to directors not employed by the Company or on its behalf	$	260	$	246	$	262
Share-based compensation to directors not employed by the Company or on its behalf		38		64		83
	$	298	$	310	$	345

Number of directors that received the above compensation by the Company		6		6		7

Salary and Benefits to Executive officers:

	Year ended December 31,
	2024		2023		2022

Salary and related benefits	$	2,412	$	2,441	$	2,543
Share-based compensation		1,123		869		231

	$	3,535	$	3,310	$	2,774

Number of people that received salary and benefits		13		10		12

Transactions with related parties:

For the year ended December 31, 2024:

	Executive officers		Certain shareholders
Revenues (see Note 5)	$	-	$	4,340
Participation in research and development expenses		-		58
Research and development expenses		698		-
Sales and marketing expenses		1,250		-
General and administrative expenses	$	1,588	$	-

For the year ended December 31, 2023:

	Executive officers		Certain shareholders
Revenues (see Note 5)	$	-	$	3,475
Participation in research and development expenses		-		115
Research and development expenses		756		125
Sales and marketing expenses		1,185		-
General and administrative expenses	$	1,369	$	-

For the year ended December 31, 2022:

	Executive officers		Certain shareholder
Revenues (see Note 5)	$	-	$	811
Other income		-		3,500
Participation in research and development expenses		-		1,898
Research and development expenses		570		297
Sales and marketing expenses		1,098		-
General and administrative expenses	$	1,111	$	-